Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas
Primary Purpose
Malignant Glioma of Brain
Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
5ALA exoscopic fluorescence filter
Sponsored by
About this trial
This is an interventional device feasibility trial for Malignant Glioma of Brain
Eligibility Criteria
Inclusion Criteria:
- Male and female ≥ 18 years of age
- Must have a suspected or biopsy-proven glioma (World Health Organization grade II or IV), new or recurrent
- Indication for craniotomy for removal of a suspected or recurrent brain tumor
- Karnofsky Performance Scale ≥ 60%
- Willing and able to provide informed consent or have surrogate consent by legally authorized representative
Exclusion Criteria:
- Male and female < 18 years of age
- Porphyria, hypersensitivity to porphyrins
- Renal insufficiency as defined by a creatinine > 2.0 mg/dL
- Hepatic insufficiency as diagnosed in preoperative medical clearance evaluation
- Females of childbearing potential with a positive pregnancy test
- Nursing women
- Unwilling or unable to provide informed consent
Sites / Locations
- Lenox Hill HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Patients with new or recurrent malignant gliomas
Arm Description
Outcomes
Primary Outcome Measures
Focal Distance
To characterize optimal focal distance on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal
Light Intensity
To characterize optimal light intensity settings on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal
Working Angle
To characterize optimal working angle position on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal
Secondary Outcome Measures
Usability of 5ALA exoscope filter as assessed by overall surgery length
To determine functionality and performance reliability of the blue light excitation filter on the ORBEYE exoscope platform with overall surgery length
Usability of 5ALA exoscope filter as assessed by surgeon qualitative assessment
To determine functionality and performance reliability of the blue light excitation filter on the ORBEYE exoscope platform with surgeon qualitative assessment
Full Information
NCT ID
NCT04937244
First Posted
June 8, 2021
Last Updated
June 17, 2021
Sponsor
Northwell Health
Collaborators
Olympus Corporation
1. Study Identification
Unique Protocol Identification Number
NCT04937244
Brief Title
Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas
Official Title
Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Unknown status
Study Start Date
May 13, 2021 (Actual)
Primary Completion Date
May 11, 2022 (Anticipated)
Study Completion Date
May 11, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Northwell Health
Collaborators
Olympus Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Fluorescence-guided resection using 5-ALA induced tumor fluorescence of malignant gliomas allows for better identification of tumor tissue and more radical resection in select patients and improvements in progression-free and overall survival. With new developments in surgical microscopy, the development of digital exoscopes have provided advanced visualization as well as improvements in ergonomics and accessibility of the surgical field. The use of the exoscope in 5-ALA fluorescence-guided tumor surgery has the potential to enhance the ability of the surgeon to remove brain tumors with high efficacy. While algorithms for use of 5-ALA fluorescence have been optimized for use with traditional microscopes, the use of fluorescence techniques in newer digital exoscopes have not been developed. The primary outcome of the study is to obtain parameters to optimize visualization of fluorescence intensity and perform optimization based on the intensities achieved. The operating ORBEYE exoscope will be fitted with a blue light filter. All experiments will be performed in darkened operating rooms. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. Patients (experimental group) will receive 5ALA treatment before operation, blue light filter imagining will take place after tacking up dura and prior to direct resection. The expected outcomes of image analysis will be to have a set of exoscope parameters optimized for visualization of 5ALA tissue in different tumor types. This 5ALA characterization of visualization parameters has never been completed on an exoscope. Optimizing ORBEYE exoscope parameters will define a standard in glioma resection using 5ALA under a novel exoscopic filter as well as contribute insight into the use of the fluorescent filter for additional tumor types.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malignant Glioma of Brain
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients with new or recurrent malignant gliomas
Arm Type
Experimental
Intervention Type
Diagnostic Test
Intervention Name(s)
5ALA exoscopic fluorescence filter
Intervention Description
Visualization of tumor tissue with 5ALA will be done in the operating room to localize neoplastic tissue. The operation will be conducted in a standard fashion uninfluenced by the imaging on the ORBEYE exoscope. The ORBEYE exoscope will be used with the blue light filter after tacking up dura upon first visualization of tumor tissue prior to direct resection. Images will be taken prior to, during and at the end of the planned resection. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. The ORBEYE exoscope or standard operating microscope (depending on surgeon preference) will then be used in the standard fashion of an operative microscope with a fluorescent filter, to assist with surgical resection as per the surgeon's preference. Resection will proceed according to current standard of care.
Primary Outcome Measure Information:
Title
Focal Distance
Description
To characterize optimal focal distance on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal
Time Frame
6 weeks
Title
Light Intensity
Description
To characterize optimal light intensity settings on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal
Time Frame
6 weeks
Title
Working Angle
Description
To characterize optimal working angle position on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Usability of 5ALA exoscope filter as assessed by overall surgery length
Description
To determine functionality and performance reliability of the blue light excitation filter on the ORBEYE exoscope platform with overall surgery length
Time Frame
6 weeks
Title
Usability of 5ALA exoscope filter as assessed by surgeon qualitative assessment
Description
To determine functionality and performance reliability of the blue light excitation filter on the ORBEYE exoscope platform with surgeon qualitative assessment
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female ≥ 18 years of age
Must have a suspected or biopsy-proven glioma (World Health Organization grade II or IV), new or recurrent
Indication for craniotomy for removal of a suspected or recurrent brain tumor
Karnofsky Performance Scale ≥ 60%
Willing and able to provide informed consent or have surrogate consent by legally authorized representative
Exclusion Criteria:
Male and female < 18 years of age
Porphyria, hypersensitivity to porphyrins
Renal insufficiency as defined by a creatinine > 2.0 mg/dL
Hepatic insufficiency as diagnosed in preoperative medical clearance evaluation
Females of childbearing potential with a positive pregnancy test
Nursing women
Unwilling or unable to provide informed consent
Facility Information:
Facility Name
Lenox Hill Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10075
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Randy D'Amico
Phone
347-563-6587
Email
rdamico8@northwell.edu
First Name & Middle Initial & Last Name & Degree
Randy D'Amico, MD
First Name & Middle Initial & Last Name & Degree
John Boockvar, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30135440
Citation
Belykh E, Miller EJ, Patel AA, Bozkurt B, Yagmurlu K, Robinson TR, Nakaji P, Spetzler RF, Lawton MT, Nelson LY, Seibel EJ, Preul MC. Optical Characterization of Neurosurgical Operating Microscopes: Quantitative Fluorescence and Assessment of PpIX Photobleaching. Sci Rep. 2018 Aug 22;8(1):12543. doi: 10.1038/s41598-018-30247-6.
Results Reference
background
PubMed Identifier
31529083
Citation
Langer DJ, White TG, Schulder M, Boockvar JA, Labib M, Lawton MT. Advances in Intraoperative Optics: A Brief Review of Current Exoscope Platforms. Oper Neurosurg (Hagerstown). 2020 Jul 1;19(1):84-93. doi: 10.1093/ons/opz276.
Results Reference
background
PubMed Identifier
26308630
Citation
Hadjipanayis CG, Widhalm G, Stummer W. What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas? Neurosurgery. 2015 Nov;77(5):663-73. doi: 10.1227/NEU.0000000000000929.
Results Reference
background
Learn more about this trial
Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas
We'll reach out to this number within 24 hrs